In the Margins
French pharmaceutical company Sanofi said it will seek to replace the board of Medivation after the American drug maker’s directors rejected a $9.3 billion takeover offer. Sanofi said in April that Medivation’s directors had failed to respond to its approach. Meanwhile, Medivation’s board called the offer “inadequate,” and founder and CEO David Hung has said the French company’s move was “opportunistically timed.” Read the original story from The New York Times.
Most Read
Cybersecurity continues to be an area of focus for the Securities and Exchange Commission staff and an important area of oversight for directors of investment companies. ...
Thrivent Financial is entering the interval fund business and has assembled a new board to oversee its first offering, the soon-to-be-launched Thrivent Church Loan & Income Fund. ...
Independent mutual fund directors saw markedly smaller increases in pay in 2017, when compared to the year prior, according to the results of the Independent Directors ...
The parties in a 2014 lawsuit accusing PIMCO of overcharging Total Return Fund shareholders while lavishly compensating CIO Bill Gross and CEO Mohamed El-Erian agreed this week ...